Kala azar

Version: November 2025

Introduction

Kala azar, also known as visceral leishmaniasis, is a severe parasitic disease caused by the protozoan parasites of the genus Leishmania. The disease is transmitted to humans through the bite of infected female sandflies. Kala azar is characterized by irregular bouts of fever, weight loss, enlargement of the spleen and liver, and anemia. It is endemic in parts of Asia, Africa, South America, and the Mediterranean. Without treatment, Kala azar can be fatal, making early diagnosis and appropriate therapy essential. Efforts to control the disease focus on vector control, early diagnosis, effective treatment, and surveillance.

Highlights

Analysis

Cases Analysis

Kala-azar, or visceral leishmaniasis, in mainland China from 2015 to 2025 shows significant fluctuations in cases but a consistently low mortality rate. The highest recorded cases occurred in November 2015 (123 cases), but numbers thereafter stabilized, mainly fluctuating between single digits and mid-thirties each month. Despite periodic spikes, deaths remained sporadic, with fatalities recorded in February 2016, November 2020, February 2022, February and April 2023, August and October 2023, and July 2025. This low mortality suggests effective treatment protocols, minimizing fatal outcomes even amid disease surges.

Seasonal trends are apparent, as cases generally peak during warmer months—correlating with conditions favorable for sandflies, the disease’s primary vector. The pattern indicates possible environmental influences or cyclic trends affecting transmission, reflecting ongoing vector dynamics. The introduction of robust medical interventions and public health processes ensures early detection and treatment, keeping the fatality rate low.

Overall, China’s efforts in managing Kala-azar appear successful, with disease control characterized by vigilant surveillance and strategic health measures. The focus on understanding local environmental and socioeconomic factors affecting transmission dynamics could further refine interventions, ensuring tailored approaches to mitigate outbreaks. Sustained efforts are crucial for maintaining low mortality and managing periodic case surges effectively. This highlights a strong health infrastructure capable of managing fluctuating case numbers while keeping fatalities minimal.

Deaths Analysis

An analysis of Kala azar deaths in the Chinese mainland between November 2015 and November 2025 indicates sparse fatalities amidst fluctuating case numbers. Despite periodic months with cases ranging from the low teens to mid-thirties, only eight deaths were reported, highlighting China’s effective interventions and healthcare practices in managing the disease. The sporadic deaths in February 2016, November 2020, February and April 2022, multiple months in 2023, and July 2025 suggest that severe outcomes are not directly tied to case numbers.

The absence of a clear correlation between cases and fatalities suggests other influential factors such as timely medical care and regional healthcare capabilities. For instance, February 2016 saw one death with just 52 cases, whereas March 2023 had 37 cases with no fatalities. This decoupling of case numbers from deaths underscores the critical role of efficient healthcare systems in addressing Kala azar. The persistent zero fatalities over extended periods suggests successful ongoing health interventions.

Overall, the data indicate that while Kala azar persists as a public health issue in the region, its lethality remains low due to effective healthcare strategies. These results illustrate the importance of continued surveillance and healthcare improvements to maintain low mortality rates despite variable incidence levels.

Source Data

Github